Physician profile
Ashley Bechtel
NPI 1215771720
$5,524.47
in general payments reported to CMS, 2019-2025
35 companies · $4,415 in 2025
The $4,415 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,109 · 2025: $4,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642 · Travel and Lodging: $1,821 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.18 |
| Travel and Lodging | $1,821.29 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,084.83 | 2025 | Infinity, Proclaim |
| Ucb, INC. | $439.75 | 2024-2025 | Rystiggo, Fintepla, Briviact |
| Lilly USA, LLC | $357.21 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $226.80 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $215.25 | 2024-2025 | |
| Abbvie INC. | $203.62 | 2025 | |
| Sk Life Science, INC. | $197.27 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $191.51 | 2024-2025 | Inbrija, Xeomin, Ampyra |
| Lundbeck LLC | $140.73 | 2024-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $135.15 | 2024-2025 | Ultomiris |
| Biogen, INC. | $121.45 | 2024-2025 | Skyclarys, Tysabri |
| Tg Therapeutics, INC. | $99.31 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $90.75 | 2024-2025 | Wainua |
| Inspire Medical Systems, INC. | $85.83 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $83.65 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $76.94 | 2024-2025 | |
| Tanabe Pharma America, INC. | $75.86 | 2024-2025 | Radicava |
| Cycle Pharmaceuticals INC | $67.76 | 2025 | Tascenso Odt, Bafiertam |
| Genzyme Corporation | $65.90 | 2025 | |
| Argenx US, INC. | $65.43 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Mallinckrodt Hospital Products INC. | $64.89 | 2024-2025 | Acthar |
| Emd Serono, INC. | $59.26 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $45.61 | 2025 | Austedo Xr |
| Amneal Pharmaceuticals LLC | $42.76 | 2024-2025 | Crexont, Ongentys 50mg Capsules 30 |
| Otsuka America Pharmaceutical, INC. | $38.94 | 2024 | Rexulti |
| Pfizer INC. | $36.15 | 2025 | |
| Neurelis, INC. | $28.27 | 2024 | Valtoco |
| Neurocrine Biosciences, INC. | $27.18 | 2025 | |
| Aquestive Therapeutics, INC. | $26.90 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.10 | 2025 | Caplyta |
| Ge Healthcare | $25.78 | 2025 | |
| Ani Pharmaceuticals, INC. | $23.20 | 2024 | Purified Cortrophin Gel |
| Cranial Technologies, INC | $20.08 | 2025 | Doc Band |
| Acadia Pharmaceuticals INC | $17.68 | 2025 | Nuplazid |
| Kedrion Biopharma, INC. | $16.67 | 2024 | Gammaked, Koate, Albuked |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bechtel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.